Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001126 · ClinicalTrials.gov registry record · Phase 1

Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)

A Phase 1 study of Papilloma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT00001126 is a Phase 1 study of Papilloma that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001126, a Phase 1 study of Papilloma, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children. Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved drug to treat this infection. However, cidofovir is a drug effective against several viruses. Cidofovir may be able to attack the HPV virus. This study tests the safety of giving this drug to children.

Conditions Studied

Interventions

  • DRUG Cidofovir

Study Locations (1)

Alabama

  • NIAID/DMID/CASG Central Unit - Birmingham

Trial Details

FieldValue
Enrollment Target 36 participants
Est. Completion 2005-11
Phase Phase 1

What the Registry Record Tells You About NCT00001126

The ClinicalTrials.gov registry entry for NCT00001126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Papilloma appearing as the primary indexed condition, and to 1 intervention - of which Cidofovir is the first listed.

NCT00001126 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT00001126 about?

NCT00001126 is a clinical study titled "Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)". The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children. Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved...

What is the current status of trial NCT00001126?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. Estimated completion is 2005-11.

What conditions does trial NCT00001126 study?

This clinical trial studies the following conditions: Papilloma.

What interventions are being tested in trial NCT00001126?

The interventions under investigation include: Cidofovir (DRUG).

Who is sponsoring clinical trial NCT00001126?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001126 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Papilloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.